CRC
‘Right-Sizing’ Surveillance Intervals for CRC: Considerations for Now and the Future
The 2020 guidelines for surveillance colonoscopy have steered clinicians toward more appropriate surveillance ...
AUGUST 25, 2025
Circulating Tumor DNA Blood Test Shows Promise for Colorectal Cancer Screening
A circulating tumor DNA–based blood test demonstrated its ability to accurately detect colorectal cancer ...
AUGUST 6, 2025
FDA Approves Lumakras With Vectibix for KRAS G12C–Mutated Colorectal Cancer
The FDA has approved sotorasib (Lumakras, Amgen) with panitumumab (Vectibix, Amgen) for adult patients with KRAS ...
JANUARY 21, 2025
FDA Grants Accelerated Approval to Braftovi for Some Patients With Metastatic Colorectal Cancer
The FDA granted accelerated approval to encorafenib (Braftovi, Array BioPharma, a subsidiary of Pfizer) with ...
DECEMBER 23, 2024
FDA Approves Next-Gen mt-sDNA test, Cologuard Plus
The FDA has approved the next-generation of the multitarget stool DNA test Cologuard (Exact Sciences).
OCTOBER 28, 2024
FIT Reduces Deaths From Colorectal Cancer
Evidence is emerging for the power of fecal immunochemical testing to not only reduce colorectal cancer incidence ...
SEPTEMBER 20, 2024
Increased Cancer, Death Risks After Adenomas Found at Baseline
Long-term follow-up has documented a significantly increased incidence of CRC in patients with any adenomas on ...
SEPTEMBER 9, 2024
FDA Approves First Blood-Based CRC Screener
The FDA has approved the first blood test to screen for colorectal cancer, a cell-free DNA blood-based test called ...
AUGUST 1, 2024
FDA Grants Accelerated Approval to Krazati With Erbitux for KRAS G12C–Mutated Colorectal Cancer
The FDA has granted accelerated approval to adagrasib (Krazati, Mirati Therapeutics) plus cetuximab (Erbitux, ...
JUNE 24, 2024
First-Line Options for CRC Screening: Stool-Based Screening Versus Colonoscopy
For colorectal cancer prevention, should stool-based testing be a first-line option rather than just an alternative ...
MAY 29, 2024
FDA Approves First mt-sRNA Test for CRC Screening in Average-Risk Adults
The FDA has approved the first multitarget stool RNA test for colorectal cancer screening in typical average-risk ...
MAY 27, 2024
Disparities in Survival and Driver Mutations In CRC Shown in Large Database
An evaluation of a large cohort of CRC patients has revealed substantial racial disparities in overall survival and ...
MAY 22, 2024
